Point-of-Care HbA1c Testing in Diabetes Management

Point-of-care testing for glycated haemoglobin (HbA1c) has emerged as a transformative tool in the management of diabetes, enabling clinicians to obtain near-immediate feedback on average glycaemic control directly within the consultation. By measuring the proportion of haemoglobin molecules that carry bound glucose over the preceding two to three months, HbA1c serves both as a diagnostic criterion and as a longitudinal marker of therapeutic efficacy. Traditional laboratory assays often entail delays of days or weeks before results return, hindering timely treatment adjustments and patient engagement. In contrast, portable analysers facilitate same-visit decision-making, strengthen the patient–clinician dialogue and support more frequent monitoring, particularly in primary care, rural or resource-limited settings. Robust quality assurance and calibration protocols underpin the analytical accuracy of these devices, while cost-effectiveness studies indicate that point-of-care HbA1c testing can reduce downstream complications by accelerating optimisation of glycaemic targets. The global significance of this approach lies in its capacity to extend reliable diabetes surveillance to underserved communities, to streamline care pathways and to foster more individualised treatment regimens. Practical applications span screening, confirmation of diagnosis, intensification of therapy and the evaluation of lifestyle or pharmacological interventions, with mounting evidence that immediate result availability promotes patient adherence and improves long-term outcomes.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Point-of-Care HbA1c Testing in Diabetes Management publication trend

The graph below shows the total number of articles in point-of-care hba1c testing in diabetes management across all publications each year (not limited to Nature Index journals).

Technical terms

HbA1c: Glycated haemoglobin reflecting average blood glucose over the preceding two to three months.

Point-of-care testing (POCT): Diagnostic assays performed at or near the site of patient care, yielding rapid results.

Glycaemic control: The extent to which blood glucose levels are maintained within target ranges to minimise complications.

Bland–Altman plot: A statistical method for evaluating agreement between two quantitative measurement techniques.

References

1. Using point-of-care HbA1c to facilitate the identification of diabetes and abnormal glucose regulation in primary healthcare settings. Frontiers in Public Health (2023).
2. Point-of-Care testing of HbA1c levels in community settings for people with established diabetes or people at risk of developing diabetes: A systematic review and meta-analysis. Primary Care Diabetes (2023).
3. Improving Access to the Glycated Hemoglobin Test in Rural Communities With Point-of-Care Devices: An Application Study. Frontiers in Medicine (2021).